Janux Therapeutics, a biotech with cutting-edge platforms, shows promising results in cancer treatment, making it a top buyout candidate for 2025. Read my JANX thesis.

An ultrasound test that takes less than 20 minutes could improve the accuracy of prostate cancer diagnosis, scientists say.

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Study of almost 30,000 patients finds exercise could be effective in ‘not only preventing the disease’ but later ‘fighting ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...

Most important note is- surgeries for benign enlargement removes only the center part of the prostate to clear the ...

This advanced imaging technology plays a critical role in redefining how prostate cancer is staged. PSMA-PET imaging uses tiny amounts of radioactive “tracers,” called radiotracers, that binds to ...

New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...